Analgesia and Anti-inflammatory of Osteoarthritis
Conditions
Brief summary
The study is being conducted to evaluate the efficacy, and safety of HRF2105patch in relieving pain of Osteoarthritis.
Interventions
DRUGHRF2105 patch
HRF2105 patch ，external use，once a day
DRUGLoxoprofen patch
Loxoprofen patch ，external use，once a day
DRUGplacebo
placebo ，external use，once a day
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Able and willing to provide a written informed consent 2. Male or female 3. Meeting the diagnostic criteria of knee Articular bone osteoarthritis 4. The target knee joint meeting the VAS scoring requirements 5. K-L grading II-III，and the other knee joint grading is not higher than the target side 6. Able to walk without assistance 7. Willing to take contraceptive measures, female non pregnancy or lactation period
Exclusion criteria
1. Concomitant bronchial asthma; Previous aspirin induced asthma (non steroidal anti-inflammatory drugs induced asthma) 2. Active or high-risk bleeding diseases such as gastrointestinal ulcers may worsen due to the use of NSAIDs 3. Have a history of myocardial infarction or undergo coronary artery bypass grafting surgery 4. Having serious cardiovascular, cerebrovascular, hematopoietic, metabolic system diseases or malignant tumors, as determined by the researcher, it is not suitable to participate in this study 5. The combination of mental illnesses such as depression, dementia, and schizophrenia has been determined by researchers to affect the efficacy evaluation of study drugs 6. Arthritis caused by other factors such as dermatomyositis, gouty arthritis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis, purulent arthritis, systemic lupus erythematosus 7. In addition to the knee joint, complications such as goose foot bursitis, intermittent claudication, and other conditions that can cause pain in the knee joint area 8. Severe osteoarthritis with obvious narrowing of joint space and indications for surgery 9. Pain in other areas that affect the evaluation of bone and joint pain, such as hip joint pain or lower back pain 10. Rashes and skin damage on the intended application of the study drug 11. Abnormal liver and kidney function, anemia or thrombocytopenia 12. Within one year prior to signing the ICF, either side of the knee joint experienced open knee injury or underwent other knee joint surgeries such as arthroscopy, arthroscopic debridement, knee replacement, etc 13. Patients who have received intra-articular drug injection therapy (such as glucocorticoids, sodium hyaluronate, medical chitosan, growth factors, and platelet rich plasma) on either side of the knee joint within 3 months prior to signing the ICF 14. Within the first 5 days of randomization or during the study period, other drugs for treating osteoarthritis need to be used except the study drug 15. During the research process, physical therapy and rehabilitation therapy for the lower limbs or waist are required 16. Individuals with a history of allergies or contraindications to any component of this product or other losoprofen sodium preparations 17. During this period, alcohol, drugs, and drug withdrawal may affect the effectiveness and safety evaluation of the study drug 18. Participants in other clinical trials within 3 months 19. Family members of the subjects in this study (cohabiting) 20. Clinical research center employees directly involved in the operation, management, or support of this trial, or immediate family members 21. Other situations that the researcher determines are not suitable for participating in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in VAS score from baseline at the end of treatment Day7 on rising from the chair | Day7 |
Secondary
| Measure | Time frame |
|---|---|
| Change in WOMAC stiffness score from baseline at the end of treatment (Day7) | Day7 |
| Change in WOMAC daily activity score from baseline at the end of treatment (Day7) | Day7 |
| Change in WOMAC total score from baseline at the end of treatment (Day7) | Day7 |
| Change in WOMAC pain score from baseline at the end of treatment (Day7) | Day7 |
| Researcher satisfaction score | Day7 |
| Subject satisfaction score | Day7 |
| Skin irritation and sensitization scores | Day0-Day7 |
| Daily average dose of remedial drug (Paracetamol) during the treatment period | Day0-Day7 |
Contacts
Primary ContactQin Liu
Outcome results
None listed